Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward Connor

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Science Translational Medicine|January 21, 2011
"Creating hope" and other incentives for drug development for childrenEdward Connor, Pablo Cure
Clinical Investigation|May 29, 2012
Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetingsKate Bushby, Edward Connor
Science Translational Medicine|April 7, 2010
More than baby steps: perspectives on pediatric translational researchEdward Connor, Donald Lombardi, John van den Anker
The Pediatric Infectious Disease Journal|November 12, 2005
Safety and immunogenicity of palivizumab (Synagis) administered for two seasonsDonald Null, Bernard Pollara, Penelope H Dennehy, et al.
Therapeutic Innovation & Regulatory Science|April 3, 2021
Inclusion of Adolescents in Adult Clinical Trials: Report of the Institute for Advanced Clinical Trials for Children's Pediatric Innovation Research ForumGary J Noel, Robert M Nelson, Christina Bucci-Rechtweg, et al.
Vaccine|November 19, 2023
Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and UgandaEdward Man-Lik Choi, Ggayi Abu-Baker Mustapher, Gloria Omosa-Manyonyi, et al.
The Lancet. Infectious Diseases|October 23, 2022
Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trialDaniela Manno, Agnes Bangura, Frank Baiden, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Science Translational Medicine|January 21, 2011
"Creating hope" and other incentives for drug development for childrenEdward Connor, Pablo Cure
Clinical Investigation|May 29, 2012
Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetingsKate Bushby, Edward Connor
Science Translational Medicine|April 7, 2010
More than baby steps: perspectives on pediatric translational researchEdward Connor, Donald Lombardi, John van den Anker
The Pediatric Infectious Disease Journal|November 12, 2005
Safety and immunogenicity of palivizumab (Synagis) administered for two seasonsDonald Null, Bernard Pollara, Penelope H Dennehy, et al.
Therapeutic Innovation & Regulatory Science|April 3, 2021
Inclusion of Adolescents in Adult Clinical Trials: Report of the Institute for Advanced Clinical Trials for Children's Pediatric Innovation Research ForumGary J Noel, Robert M Nelson, Christina Bucci-Rechtweg, et al.
Vaccine|November 19, 2023
Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and UgandaEdward Man-Lik Choi, Ggayi Abu-Baker Mustapher, Gloria Omosa-Manyonyi, et al.
The Lancet. Infectious Diseases|October 23, 2022
Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trialDaniela Manno, Agnes Bangura, Frank Baiden, et al.
Pageof 1